Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
about
Recent advances in oral vaccine development: yeast-derived β-glucan particlesPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineIntranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challengeOptions for improving effectiveness of rotavirus vaccines in developing countries.Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccineInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity.Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.The influence of delivery vectors on HIV vaccine efficacyIntranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.Mucosal immunity and vaccines.The effect of plant tissue and vaccine formulation on the oral immunogenicity of a model plant-made antigen in sheep.Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT)Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineDistinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesA TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig modelA second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Advances in mucosal vaccination.In vitro inhibition of transmissible gastroenteritis coronavirus replication in swine testicular cells by short hairpin RNAs targeting the ORF 7 gene.In situ characterization of CD4+ T cell behavior in mucosal and systemic lymphoid tissues during the induction of oral priming and tolerance.Recent developments in mucosal vaccines against prion diseases.Mucosal vaccine adjuvants update.Implication of nanoparticles/microparticles in mucosal vaccine delivery.Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.The Vibrio cholerae cytolysin promotes activation of mast cell (T helper 2) cytokine productionMouse models for the study of mucosal vaccination against otitis media.
P2860
Q27001699-456723B6-020D-48D8-96D6-C8F25470A0FFQ27347652-A3EDF017-0E9F-41D1-BA20-9B881F992A36Q28743895-4F849BC7-4DB8-4916-B642-D0418DE999A6Q30241442-47055D24-8619-459E-8C33-C9F1724F4393Q30421413-CCE705E4-F9A9-4646-8F7E-097715CCD156Q33611645-594C674D-694C-447F-BE5B-53841491993AQ33648677-4EAF5ABD-AD6B-42A6-B541-C29B4751EA54Q33725145-A4D0498C-2F3F-40BF-8239-A13428A41AA8Q33738499-041114C5-03EA-4D2B-9219-8DB6D8DF9B06Q33805176-DDDC2115-BE14-47B8-9C4D-4CBAEF762997Q33870830-3F04CF47-3FCF-43DB-9969-F9ECC77DF7A3Q34034242-38ACF1E3-54A7-428A-91BF-843C0C049B86Q34077543-B55837CF-6C5D-4516-819F-98DC7F7DFB5AQ34335523-A3515F8F-A59B-461E-927B-717AAF610B9DQ34409172-614C8EF7-7A7F-4B16-A3E4-F10D709B0BBCQ34534852-C9EC494B-D648-4FFA-8B12-43511FA282A7Q34548500-85EAE1E5-3315-472A-ABA9-58F070778142Q34568384-DEBAFBE2-8FB0-4A50-95D1-EDF46EEAF61CQ34625185-96699FF3-4506-4A7E-920A-B492CFE1080DQ34641267-3F4B505A-9DB9-40A1-8599-ED0F688AEA9BQ34739969-E8A033C3-D991-496C-9F20-A81A9E9B02CAQ34781602-F49EB474-9EFA-49E7-87F0-9CCFCCCE3E28Q35042764-D65EEB2D-3786-44D7-8A8E-BDADC4F962B9Q35138744-73BEB9B1-B56F-47A0-936F-1086D32C00D8Q35143128-C5956030-F125-4465-BC17-95F2C91C19CDQ35166960-F3CD69B2-F1A1-4126-940A-EAA2F0209921Q35498376-5A1305B3-262E-4D8D-94FC-3A84ACABE952Q35747402-9A58E9E0-16E8-4009-A367-09E83969FDE5Q35863373-59B9042A-5CA0-4309-940E-EC211D7F768CQ35953762-B0EAA255-825C-43F4-A057-BFDF0B40E4D9Q36177348-E5B6C88D-FC34-45D4-A364-DEABE11A0CACQ36380241-19BC35E1-FDDF-4B4E-A0A3-445BBFFEDC82Q36403793-64D85BA7-9043-4C40-AA58-CAD36DC7D339Q36728797-F034AF31-951B-4EB6-B51C-5C756E8DF370Q36758075-234505A7-058D-4B80-8397-26890F46E00BQ36837152-44A984ED-FD07-4053-9498-21499A6CABDAQ36846046-EA89CDFA-B91E-4AB5-8139-1EEE6B2D6948Q36888054-AC5F9D23-5C8F-429F-B7CF-1577795B955FQ36989717-D37E70DF-4E60-48EC-8715-EDC22A929664Q37093093-A4896748-C97A-4398-9739-ECBAE6C98528
P2860
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@ast
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@en
type
label
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@ast
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@en
prefLabel
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@ast
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@en
P2093
P1433
P1476
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
@en
P2093
Ali Mharandi
Cecil Czerkinsky
Kristina Eriksson
P304
P356
10.1016/S0264-410X(03)00206-8
P407
P478
21 Suppl 2
P50
P577
2003-06-01T00:00:00Z